AGP Picks
View all

Hygieia touts smart factory scale-up for NMNH production

Oct. 23, 2026
Hygieia touts smart factory scale-up for NMNH production
By AI, Created 08:43 UTC, Oct 23, 2026, AGP -

Hygieia used Vitafoods Asia in Shenzhen to highlight its industrial NMNH manufacturing and broader longevity-ingredient portfolio. The company says its smart bio-factory is built to deliver high-purity, scalable supply for nutraceutical brands looking for steadier production and traceability.

Why it matters: - Hygieia is positioning reliable NMNH supply as a manufacturing problem, not just a research problem. - The company is targeting nutraceutical and functional food brands that need consistent quality, batch traceability and scalable output for anti-aging formulations. - The move matters because demand for longevity ingredients is rising while buyers still struggle to secure high-purity NMNH at commercial scale.

What happened: - Hygieia showcased its Smart Bio-Factory at Vitafoods Asia in Shenzhen, Guangdong, China. - The company presented its Reduced Nicotinamide Mononucleotide, or NMNH, production platform for B2B ingredient sourcing and formulation work. - Hygieia said it is the pioneer behind the world's first commercialized bulk NMNH powder with mass production capabilities. - The company also promoted its official website as More information.

The details: - Hygieia is a high-tech biomanufacturing company based in Shenzhen. - The factory connects computational strain design with industrial fermentation and downstream purification. - The production system includes automated environmental control, real-time bioreactor monitoring and closed-loop quality tracking. - Hygieia said its Zymevolver strain construction technology and enzyme engineering platform power the manufacturing process. - The platform uses directed evolution, structural biology modeling and high-throughput screening to engineer catalytic enzymes. - Hygieia says its NMNH process converts NADH into NMNH and adenosine monophosphate, or AMP, using recombinant EcNADD enzymes. - The company separates NMNH from byproducts with C18 reverse-phase liquid chromatography. - The purified material is then aqueous-dried into an amorphous yellowish NMNH powder without harsh chemical solvents. - Hygieia says the powder has a verified purity above 95%. - The powder is designed for capsules, sublingual tablets and multi-ingredient powder blends. - Hygieia's broader ingredient portfolio includes NMN 99%, NAD Powder 99%, Nicotinamide Riboside Hydrogen Malate, ENERENCY Nicotinamide Ribose and S-1-Propenyl-L-Cysteine powder. - The company also lists Ca-AKG bulk powder, Palmitoylethanolamide 99%, Fisetin powder 98%, Urolithin A bulk powder, MitoSpermidine Spermidine Trihydrochloride, L-ergothioneine, PQQ Disodium Salt, Resveratrol, Pterostilbene, D-chiro Inositol, 5-methyltetrahydrofolate and S-Equol. - Hygieia says it provides OEM and ODM services, including custom formula design, ingredient interaction screening, dosage optimization and private label support. - The company says it can manufacture dietary capsules, oral powders and liquid formulations on automated production lines.

Between the lines: - Hygieia is framing NMNH as a next-generation NAD+ ingredient with a manufacturing advantage over traditional supplements. - The company also is using the event to sell itself as a one-stop supplier for raw materials and finished products, not just an ingredient maker. - Claims in the release about NMNH potency, tissue effects and safety are presented as product and research positioning, and they are part of Hygieia's broader commercialization pitch.

What's next: - Hygieia says it will keep scaling production through research partnerships and process development. - The company is betting that demand for reliable longevity ingredients will keep growing across global health brands. - Its next commercial push appears aimed at converting lab-level synthetic biology into repeatable industrial supply.

The bottom line: - Hygieia is trying to turn NMNH into a mainstream bulk ingredient by pairing synthetic biology with factory-scale manufacturing and contract production services.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Asia Pacific News Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia Pacific News Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.